Skip to content

A clinical research on the efficacy of remimazolam for total intravenous intubation general anesthesia

The efficacy of remimazolam for total intravenous intubation general anesthesia: a prospective and randomized clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050923
Enrollment
Unknown
Registered
2021-09-08
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia

Interventions

Group Pro:propofol, remifentanil, cisatracurium
Group Remi:remimazolam, remifentanil, cisatracurium

Sponsors

The First Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients who underwent elective urological surgery under general anaesthesia are enrolled. The inclusion criteria included: American Society of Anesthesiologists (ASA) physical status I-III, aged 18-60 years, and competent to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients undergoing intraspinal anaesthesia or peripheral nerve block (except for postoperative analgesia). 2. Emergency surgery; heart surgery, transplantation, neurosurgery, beach surgery, controlled hypotension or pressor surgery. 3. Patients with difficult airway. 4. Patients with alcoholics and drug addicts. 5. Patients with delayed gastric retention or gastric emptying. 6. Patients with hypersensitivity to the study drug. 7. Patients with end-stage renal failure. 8. Patients with severe hypertension (systolic blood pressure = 200 mmHg, or diastolic blood pressure = 120 mmHg). 9. Patients with bilirubin 3.0mg/dl within 7 days, or aspartate aminotransferase or alanine aminotransferase increased by more than 3 times. 10. Vulnerable groups (infants, pregnant women, elderly patients, and language barrier). 11. Patients with acute narrow angle glaucoma, shock or coma, myasthenia gravis, acute alcoholism or abnormal laboratory values.

Design outcomes

Primary

MeasureTime frame
Efficacy;

Secondary

MeasureTime frame
vital signs;characteristic of anaesthesia and surgery;

Countries

China

Contacts

Public ContactGuan Xuehai

The First Affiliated Hospital of Guangxi Medical University

guan_xh@aliyun.com+86 185 8769 7310

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026